Warren Buffett bets £4bn on this! Should I buy UK pharma now?

Self-made billionaire Warren Buffett has just made a huge £4bn bet on this industry. As a UK investor, here’s what I’d do now.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The giant investment fund run by Warren Buffett, Berkshire Hathaway, has doubled down on pharmaceutical companies in the wake of the pandemic. 

All US funds that manage over $100m must submit filings with the Securities and Exchange Commission each financial quarter.

And it’s a 13-F filing from 16 November that shows exactly what Warren Buffett bought. The billionaire spent over $5.5bn (£4.3bn) on four drug companies between July and September 2020. 

They are Pfizer, Merck, AbbVie, and Bristol-Myers Squibb

The decade of pharma

Buffett clearly believes we are entering an age of massive new investment in pharmaceutical products. Investors on both sides of the Atlantic tend to hang on his every word. And so there could be some useful clues here about the trends that will define the next 20 years. 

It’s not just about investing in toilet paper manufacturers. Although it is fair to say that small AIM companies like the £100m market cap Accrol Group may have benefited from early pandemic panic buying. 

Instead the big bet by Buffett hangs on the idea that governments were caught on the hop by the outbreak. They won’t want to be put in the same position again. So we infer that they will have much larger budgets for buying and supporting vaccines, antiviral and antibacterial treatments.

Follow Warren Buffett

UK investors who want to follow Buffett can do one of two things. They can fill out a W8-BEN form if they are investing in an ISA. This is a regulatory compliance thing which means they are allowed to buy stakes in US companies. Or, they can pick the FTSE 100, FTSE 250 or AIM-listed companies they think Buffett would choose. 

Remember: Buffett buys companies he thinks have a very long runway for future success. He bets big, then creams off dividend income for as long as he possibly can. Buffett famously said: “Our favourite holding period is forever.

So two FTSE 100-listed pharmas that spring to mind are Astrazeneca and GlaxoSmithKline. The latter has a much better dividend payout of 5.75%, which usually forms part of my calculations. 

Research, then develop

R&D is can be ruinously expensive. And there’s no guarantee that there will be a successful product at the end of it. 

Drug development firms can burn through millions of investor cash without ever making a profit. And the smaller the company, the more likely this is to happen. That’s probably why Buffett is focused on the world’s largest pharma firms.

There are simply better economies of scale inside the Astrazenecas and GlaxoSmithKlines of this world. That’s because they are already selling profitable products which support expensive R&D. 

I would also avoid companies in the Covid-19 testing business, simply because Covid-19 vaccines are coming in 2021. The major revenue source that has pushed them to new heights is probably cut off for good. I’m thinking of the likes of Omega Diagnostics, Avacta, and Synairgen

If I’m a more adventurous investor? I would be looking at contract research organisations (CROs). These businesses help design clinical trials, process data, and run studies. It’s a picks and shovels play. That why I think it’s what Buffett would choose. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

TomRodgers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended Bristol Myers Squibb. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »